TD Cowen analyst Cai von Rumohr raised the firm’s price target on Leidos to $155 from $140 and keeps a Buy rating on the shares. The firm said its Q1 big beat and healthy momentum in the leveraged medical exams business suggests hiked 2024 adj. EPS guide may have opportunity. A further but much narrower gain is likely in 2025 given the stiff base for comparison.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LDOS: